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Abstract
Alcohol consumption is the key risk factor for the development of esophageal squamous cell carcinoma (ESCC), and 
acetaldehyde, a metabolite of alcohol, is an alcohol-derived major carcinogen that causes DNA damage. Aldehyde 
dehydrogenase2 (ALDH2) is an enzyme that detoxifies acetaldehyde, and its activity is reduced by ALDH2 gene 
polymorphism. Reduction in ALDH2 activity increases blood, salivary and breath acetaldehyde levels after alcohol intake, 
and it is deeply associated with the development of ESCC. Heavy alcohol consumption in individuals with ALDH2 gene 
polymorphism significantly elevates the risk of ESCC; however, effective prevention has not been established yet. In this 
study, we investigated the protective effects of Alda-1, a small molecule ALDH2 activator, on alcohol-mediated esophageal 
DNA damage. Here, we generated novel genetically engineered knock-in mice that express the human ALDH2*1 (wild-type 
allele) or ALDH2*2 gene (mutant allele). Those mice were crossed, and human ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 
knock-in mice were established. They were given 10% ethanol for 7 days in the presence or absence of Alda-1, and we 
measured the levels of esophageal DNA damage, represented by DNA adduct (N2-ethylidene-2′-deoxyguanosine). Alda-1 
significantly increased hepatic ALDH2 activity both in human ALDH2*1/*2 and/or ALDH2*2/*2 knock-in mice and reduced 
esophageal DNA damage levels after alcohol drinking. Conversely, cyanamide, an ALDH2-inhibitor, significantly exacerbated 
esophageal DNA adduct level in C57BL/6N mice induced by alcohol drinking. These results indicate the protective effects of 
ALDH2 activation by Alda-1 on esophageal DNA damage levels in individuals with ALDH2 gene polymorphism, providing a 
new insight into acetaldehyde-mediated esophageal carcinogenesis and prevention.
Introduction
Esophageal squamous cell carcinoma (ESCC) is the disease with 
high morbidity and mortality (1,2). Alcohol consumption is the 
major risk factor for ESCC, and acetaldehyde, a metabolite of 
ethanol, is considered to play a central role in alcohol-related 
esophageal carcinogenesis (3–5). Acetaldehyde causes various 
DNA damages, such as DNA adducts including N2-ethylidene-
2′-deoxyguanosine (N2-ethylidene-dG) (6) and N2-ethyl-2′-
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breaks, point mutations, sister chromatid exchanges and DNA–
DNA cross-links (8–13). ‘Acetaldehyde associated with alcohol 
consumption’ is designated as a definite carcinogen for the 
esophagus (14).
Acetaldehyde is detoxified to acetic acid by aldehyde de-
hydrogenase 2 (ALDH2) mainly in the liver (15). ALDH2 gene 
has two major alleles, ALDH2*1 (active ALDH2) and ALDH2*2 
(inactive ALDH2) (16). ALDH2*2 (rs671) allele, also known as 
Glu504Lys, encodes the ALDH2 protein, which is defective at 
metabolizing acetaldehyde (17). Combination of ALDH2*1 and 
ALDH2*2 alleles makes up three genotypes with various enzym-
atic activity; wild-type (ALDH2*1/*1), heterozygous (ALDH2*1/*2) 
and homozygous (ALDH2*2/*2) (18,19). As ALDH2*2 acts in a 
dominant negative manner (20), hepatic activity of hetero-
zygous (ALDH2*1/*2) and homozygous (ALDH2*2/*2) mutant 
ALDH2 is less than 10% and 0%, respectively, compared with 
that of wild-type (ALDH2*1/1) ALDH2 (21–23). ALDH2*2/*2 car-
riers do not tolerate alcohol and few of them habitually drink 
alcoholic beverages, meanwhile, ALDH2*1/*2 carriers may drink 
various amount of alcohol (24,25). Previous epidemiological 
analysis showed that ALDH2*1/*2 carriers with heavy alcohol 
consumption are at high risk for ESCC (26–28). According to a 
meta-analysis, ALDH2*1/*2 carriers have a 7.12-fold increased 
risk of ESCC, compared with ALDH2*1/*1 carriers (29). Moreover, 
alcoholics with the ALDH2*1/*2 carriers have a 13.5-fold in-
creased risk of ESCC, compared with ALDH2*1/*1 carriers (30). 
Thus, the risk of ESCC in ALDH2*1/*2 carriers rises according to 
the amount of alcohol consumption (31). Of note, about 70% of 
ESCC patients in East Asian countries such as Japan or Taiwan 
are revealed to have ALDH2*2 allele carriers (32,33).
Alcohol intake increases acetaldehyde concentrations in the 
blood, saliva and the breath, and ALDH2 gene polymorphisms 
affect those levels (34–36). Importantly, salivary acetalde-
hyde concentration reaches a high level in individuals with 
ALDH2*1/*2 after alcohol consumption (37). Consequently, high 
acetaldehyde-containing saliva can be directly exposed to the 
pharynx and esophagus and may induce various acetaldehyde-
mediated DNA damages in these individuals. Indeed, esophageal 
DNA damage levels in ALDH2 knockout mice were much higher 
than those in control ALDH2 wild-type mice after drinking 10% 
ethanol for 2 months (38,39).
Thus, impaired ALDH2 activity due to ALDH2 gene poly-
morphism is considered to be deeply involved in esophageal 
carcinogenesis. Therefore, restoration of ALDH2 activity might 
be beneficial to ALDH2*1/*2 carriers in ESCC prevention. At pre-
sent, a small molecule Alda-1 has been identified as an ALDH2 
activator (40,41). Here, we hypothesized that Alda-1 may reduce 
esophageal DNA injury in the ALDH2*2 allele carriers with al-
cohol consumption. To verify that hypothesis, we generated 
novel genetically engineered knock-in mice that express the 
human ALDH2*1 and/or ALDH2*2 and investigated the effects of 
Alda-1 on these knock-in mice.
The aim of this study was to clarify whether Alda-1 has 
protective effects against alcohol-derived DNA damage in the 
esophagus of ALDH2*2 allele carriers.
Materials and methods
Mouse preparation
Age-matched control C57BL/6N male mice, which carry the wild-type Aldh2 
gene, were purchased from Charles River Laboratories Japan (Yokohama, 
Japan). All experiments conformed to the relevant regulatory standards 
and were approved by the institutional animal care and use committee of 
Kyoto University (Med Kyo 16196). To obtain tissues from mice, they were 
euthanized painlessly under anesthesia with diethyl ether inhalation fol-
lowed by cervical dislocation. For the measurement of DNA adduct levels, 
esophageal tissues were frozen in liquid nitrogen and stored at –80°C until 
use. Liver tissues were collected in liquid nitrogen and stored at –80°C for 
analysis of ALDH activity.
Generation of genetically engineered knock-in mice 
that express the human ALDH2*1 (wild-type allele) 
or ALDH2*2 gene (mutant allele)
Human ALDH2*1 or ALDH2*2 knock-in mice in C57BL/6N background were 
generated by homologous recombination in TransGenic (Fukuoka, Japan) 
in accordance with the institutional guidelines. We designed targeting 
vector to replace mouse Aldh2 gene with human ALDH2*1 or ALDH2*2 
complementary DNA (cDNA) (Figure 1A). The design of the vector con-
struction is summarized in Figure 1B. As 5´ homologous arms, we used a 
2.6k base pair (bp) mouse genomic fragment containing 5´ untranslated 
region (UTR) of exon 1 of Aldh2 gene. As 3´ homologus arms, we used a 5.1k 
bp fragment containing exon 3–7 of Aldh2 gene. These genomic fragments 
were amplified by PCR from RENKA ES cell genomic DNA (42).
Mouse Aldh2 5´ UTR sequence was amplified by PCR from RENKA ES 
cell genomic DNA and cloned into a vector, named pUC118 generated by 
TransGenic, followed by human ALDH2 (ALDH2*1 or ALDH2*2) cDNA frag-
ment (1554 bp) and bovine growth hormone polyA signal (5´ UTR + cDNA 
+ polyA).
3´ homologous arm was amplified by PCR and cloned into a vector, 
named pPND2.1 generated by TransGenic, which contains lox-P flanked 
PGK_neo cassette (phosphoglycerate kinase 1 promoter-driven neomycin 
resistant gene) as a positive selection marker and MC1_DTA cassette 
(polyoma enhancer/herpes simplex virus thymidine kinase promoter 
driven diphtheria toxin A gene) as a negative selection marker.
Then, PCR-amplified 5´ homologous arm and 5´ UTR + cDNA + polyA 
were subcloned into the plasmid with 3´ homologous arm, PGK_neo cas-
sette and MC1 DTA cassette. Resulting targeting vector contains MC1_DTA 
cassette, 5´ homologous arm, human ALDH2 (ALDH2*1 or ALDH2*2) cDNA 
fragment, polyA, lox-P flanked PGK_neo cassette and 5.1  kb 3’ homolo-
gous arm. Thus, ALDH2*1 or ALDH2*2 targeting vector was generated. To 
amplify the fragment from genomic DNA, primer sets as shown in Table 1 
were used.
This targeting vector was linearized and introduced into RENKA ES 
cells (C57BL/6N) by electroporation. After selection using neomycin, the 
resistant clones were isolated, and their DNAs were screened for homolo-
gous recombination by PCR using following primer set: sc_5AF2: 5´-ACC 
ATC CAT TCA AGG TAA AGT TCC -3´ and neo_108r: 5´-CCT CAG AAG AAC 
TCG TCA AGA AG-3´. PCR positive ES clones were expanded, and isolated 
DNAs were further analyzed by PCR amplification using following primer 
sets: sc_5AF2 and neo_108r for 5´ amplification, sc_3AR3: 5´-CAG GCA CAG 
GTT ACT ACT CTT CC-3´ and neo_MS: 5´-ATT CGC AGC GCA TCG CCT TCT 
ATC GCC TTC -3´ for 3´ amplification. Homologous recombination of these 
clones was also confirmed by genomic Southern hybridization probed 
with neomycin-resistant gene.
Homologous recombinant ES cell clones were aggregated with ICR 8 
cell embryos to generate chimeric mice. Germline transmitted heterozy-
gous ALDH2 knock-in mice (F1 heterozygous ALDH2*1 or ALDH2*2 knock-in 
mice) were obtained by crossing chimeric mice with a high contribution of 
the RENKA background with C57BL/6N mice. Targeted allele was identified 
by PCR with the following primer sets: sc_5AF2 and neo_108r.
F1 heterozygous ALDH2*1 or ALDH2*2 knock-in mice were crossed each 
other to obtain F2 homozygous ALDH2*1 or ALDH2*2 knock-in mice. The 
F2 homozygous mice were crossed with B6.Cg-Tg (CAG-Cre) CZ-MO2Osb 
Abbreviation 
ALDH2 aldehyde dehydrogenase 2
cDNA complementary DNA
ESCC esophageal squamous cell carcinoma
N2-Et-dG N2-ethyl-2′-deoxyguanosine
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mice (CAG-Cre mice), which was provided by the RIKEN BRC (Tsukuba, 
Japan), to eliminate neomycin-resistant gene. Consequently, human 
ALDH2*1/*1 or ALDH2*2/*2 knock-in mice were generated. And then, the 
human ALDH2*1/*1 and ALDH2*2/*2 knock-in mice were crossed to gen-
erate human ALDH2*1/*2 knock-in mice.
The genotype of Aldh2 mice and human ALDH2 mice was con-
firmed by PCR amplification using DNA extracted from mouse tails. 
The primers used to identify mouse Aldh2 were as follows: forward, 
5′-GAGGACTGTGTTGGGAGGTC-3′; reverse, 5′-GTAGGTCCGGTCCCGTTC-3′ 
(264  bp fragment). The PCR conditions used were 94°C for 3  min, fol-
lowed by 30 cycles of 94°C for 30 s, 62°C for 30 s and 72°C for 30 s. A final 
extension was conducted at 72°C for 3 min. The primers used for the de-
tection of human ALDH2 were as follows: forward, 5′-AGATGTGCAGGATG
GCATGACC-3′; reverse, 5′-ACCCGGTAGAATTTCGACGACC-3′ (790  bp frag-
ment). The PCR conditions used were 94°C for 3 min, followed by 30 cycles 
of 98°C for 10 s, 62°C for 30 s and 68°C for 1 min. A final extension was 
conducted at 68°C for 3 min. To confirm the elimination of the neomycin-
resistance gene, we used the following primers: forward, 5′-AGATGTGC
AGGATGGCATGACC-3′; reverse, 5′-GGATGCTATGAGCTTCATTC-3′ (748  bp 
fragment). The PCR conditions used were 94°C for 3 min, followed by 30 
cycles of 98°C for 10 s, 62°C for 30 s and 68°C for 2 min. A final extension 
was conducted at 68°C for 3 min.
Figure 1. Scheme of human ALDH2*1 or ALDH2*2 targeting vector to generate genetically engineered knock-in mice that express the human ALDH2*1 or ALDH2*2 gene. 
(A) Human ALDH2 (ALDH2*1 or ALDH2) cDNA knock-in strategy. bp: base pair. (B) Construction for human ALDH2*1 or ALDH2*2 knock-in targeting vector. 5´ homologous 
arm (2.6k bp), 5´ UTR of exon 1 of Aldh2 gene + human ALDH2 (ALDH2*1 or ALDH2) cDNA (1554 bp) + polyA containing vector, and 3´ homologous arm (5.1k bp) are in-
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In addition, the genotype of human ALDH2*1 and/or ALDH2*2 was 
confirmed by the PCR-restriction fragment length polymorphism (RFLP) 
methods (43). We used the specific restriction enzyme, AcuI (R0641S, New 
England Biolabs Tokyo, Japan), to distinguish between human ALDH2*1 
and ALDH2*2. The PCR conditions for AcuI digestion were 37°C for 90 min, 
followed by 65°C for 20 min.
Measurement of enzymatic hepatic ALDH2 activity 
in mice
Hepatic ALDH2 activity in mice was determined as described previously 
(40). Briefly, it was determined spectrophotometrically by using extracted 
protein from tissue homogenate by monitoring the reductive reaction of 
NAD+ to NADH at λ340 nm. All the assays were carried out at 25°C in 0.1 
M sodium pyrophosphate buffer, pH = 9.5, 2.4 mM NAD+ and 10 mM acet-
aldehyde as the substrate.
Measurement of esophageal N2-ethylidene-dG levels 
in mice
Esophageal N2-ethylidene-dG level was quantified as described previously 
(44). Briefly, DNA was isolated from esophageal tissue specimens. NaBH3CN 
(100 mM; 156159, Sigma–Aldrich, St. Louis, MO), a reducing reagent, was 
added to DNA samples. This converts N2-ethylidene-dG to stable N2-Et-dG. 
As the endogenous N2-Et-dG level in tissues is extremely low, the N2-Et-dG 
level that is converted from N2-ethylidene-dG indicates the endogenous 
N2-ethylidene-dG level (45). The DNA adduct standard, N2-Et-dG and its 
stable isotope, [U-15N5]-labeled N2-Et-dG, were synthesized as described 
previously (46). DNA samples were digested as described previously (46) 
and subjected to liquid chromatography-tandem mass spectrometry 
(LC/MS/MS). LC/MS/MS analyses were performed using a Shimadzu LC 
system (Shimadzu Corp., Kyoto, Japan) interfaced with a Quattro Ultimo 
triple-stage quadrupole mass spectrometer or an ACQUITY UPLC H-Class 
system interfaced with a XEVO-TSQ triple-stage quadrupole mass spec-
trometer (Waters Corp., Milford, MA), as reported previously (46). Shim-
pack XR-ODS columns (3.0 × 75 mm, 2.2 μm; Shimadzu Corp.) or ACQUITY 
UPLC BEH C18 columns (2.1 × 100 mm, 1.7 μm; Waters Corp.) were used to 
separate the samples.
Single injection of Alda-1, an ALDH2 activator, on 
ALDH2 knock-in mice
To examine the effects of Alda-1 on ALDH2 activation, we injected Alda-1 
(20 mg/kg body weight; SML-0462, Sigma–Aldrich) or vehicle control (di-
methyl sulfoxide, 472301, Sigma–Aldrich) intraperitoneally on ALDH2*1/*1, 
ALDH2*1/*2 and/or ALDH2*2/*2 knock-in mice. Liver of those mice was col-
lected 3 h after the injection and used for measuring the hepatic ALDH 
activity.
Alda-1 treatment in ALDH2 knock-in mice with 
alcohol drinking
ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 knock-in mice were given 
10% ethanol instead of water and allowed to drink freely and injected 
intraperitoneally with either Alda-1 (20 mg/kg body weight twice a day, n = 8) 
or vehicle control (dimethyl sulfoxide, n = 8) every 12 h for 7 days. And the 
esophageal tissues were collected for measuring N2-ethylidene-dG levels.
Single injection of cyanamide, an ALDH2-inhibitor, 
on C57BL/6N mice
Cyanamide (187364, Sigma–Aldrich), a well-established ALDH2-inhibitor 
(47), was dissolved in distilled water. We injected cyanamide (1.5 mg/kg 
body weight) or distilled water intraperitoneally in male C57BL/6N mice, 
and then hepatic ALDH activity was measured at 2 h after the injection.
Cyanamide treatment on alcohol drinking in 
C57BL6 mice
Male C57BL/6N mice were allowed to drink 10% ethanol freely and were 
injected intraperitoneally with either cyanamide (1.5 mg/kg body weight, 
twice a day, n  =  6) or vehicle control (distilled water, n  =  6) every 12  h 
for 7  days, and the esophageal tissues were collected to measure N2-
ethylidene-dG level.
TaqMan gene expression assays
RNA was isolated using RNeasy Plus Mini Kits (QIAGEN, Hilden, Germany) 
and cDNA was synthesized using PrimeScript RT reagent kits (Takara Bio, 
Kusatsu, Japan) according to the manufacturer’s instructions. Real-time 
reverse-transcription PCR was conducted with TaqMan Gene Expression 
Assays (Life Technologies Corp., Tokyo, Japan) for ALDH2 (Assay ID; 
Hs01007998_m1) and for β-actin (Assay ID; Hs99999903_m1) using a 
LightCycler 480 Instrument II (Hoffmann-La Roche Ltd., Basel, Switzerland) 
as described previously (48). All PCRs were performed in triplicate. The 
relative ALDH2 messenger RNA expression level was normalized to that of 
β-actin as an internal control.
Western blot analysis
Hepatic whole-cell lysates were prepared as described previuosly (49). 
The denatured protein samples (20 μg) were fractionated on Any kD Mini-
PROTEAN TGX Precast Gels (Bio-Rad Laboratories, Hercules, CA). Primary 
antibodies and the titers used for western blotting were as follows: goat 
polyclonal anti-ALDH2 (N-14) (sc-48838; Santa Cruz Biotechnology, Santa 
Cruz, CA;1:1000); rabbit monoclonal anti-β-actin (13E5; Cell Signaling 
Technology; 1:2000). These were then reacted with the appropriate horse-
radish peroxidase-conjugated secondary antibody (GE Healthcare, Little 
Chalfont, UK). The signal was visualized using an Immobilon Western 
Chemiluminescent Horseradish Peroxidase Substrate (Merck Millipore, 
Darmstadt, Germany) and was exposed using a ChemiDoc XRS system 
equipped with Image Lab software (Bio-Rad Laboratories).
Statistical analysis
Data are presented as the mean ± standard deviation. The data were first 
tested for normality of distribution. The differences between two groups 
were analyzed using two-tailed paired Student’s t-tests for equal variance 
data. P-values of less than 0.05 were considered significant.
Table 1. Primer sets for amplification from genomic DNA
Primer name Sequence(5´-3´) Size (mer)
PCR for 5´ homologous arm
Forward 5AF1 CAC TAT CTT CTT CTT CCC TGT GC 23
Reverse 5AR1 GAA GTG AGT CTC ACC TGG TTG C 22
PCR for 3´ homologous arm
Forward 3AF1 TGA ATG AAG CTC ATA GCA TCC 21
Reverse 3AR1 GGT CCT TTG TAG GAG GTT ACA GC 23
5´ PCR for screening
Forward sc_5AF2 CC ATC CAT TCA AGG TAA AGT TCC 23
Reverse neo_108r CCT CAG AAG AAC TCG TCA AGA AG 23
3´ PCR for screening
Forward neo_MS ATT CGC AGC GCA TCG CCT TCT ATC GCC TTC 30
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Results
Generation of human ALDH2*1/*1, ALDH2*1/*2, or 
ALDH2*2/*2 knock-in mice
To confirm the generation of human ALDH2 (ALDH2*1 or 
ALDH2*2) gene knock-in mice, we first checked the deletion of 
mice Aldh2 gene and insertion of human ALDH2 gene by PCR 
using the primers specifically recognizing mice Aldh2 or human 
ALDH2. As shown in Figure 2A, control C57BL/6N mice (mice/
mice) were positive for mice Aldh2 and negative for human 
ALDH2. F1 heterozygous human ALDH2 knock-in mice (mice 
Aldh2/human ALDH2*1 or ALDH2*2) showed positive for both 
mice Aldh2 and human ALDH2. F2 homozygous human ALDH2 
knock-in mice (human ALDH2*1/*1 or ALDH2*2/*2) showed nega-
tive for mice Aldh2 and positive for human ALDH2.
Next, we eliminated neomycin-resistant gene in F2 homozy-
gous human ALDH2*1/*1 or ALDH2*2/*2 knock-in mice by crossed 
with CAG-Cre mice, and its absence was confirmed by PCR. 
When the mice possess the neomycin-resistant gene, 2498 bp 
bands are seen. On the other hand, 748 bp bands are observed 
when neomycin-resistant gene is deleted (Figure 2B).
Next, in F2 homozygous human ALDH2 knock-in mice, we 
checked the genotype (i.e. either ALDH2*1/*1, ALDH2*1/*2 or 
ALDH2*2/*2) by PCR-RFLP method. After digestion by restriction 
enzyme AcuI, PCR products derived from human ALDH2*1/*1 
knock-in mice were recognized by showing three bands at 
430 bp, 235 bp and 83 bp, whereas those from human ALDH2*2/*2 
knock-in mice presented with two bands at 665 bp and 83 bp. 
After cleavage by AcuI, PCR products derived from human 
ALDH2*1/*2 knock-in mice showed four bands at 665 bp, 430 bp, 
235 bp and 83 bp, and thus, human ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*2/*2 knock-in mice were generated, and hereafter, those 
mice are described as ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 
mice, respectively.
Characterization of ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*1/*2 mice
We then characterized ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 
mice, in terms of expression and enzymatic activity of ALDH2. 
When measured using liver tissue homogenate, the ALDH2 mes-
senger RNA (Figure 3A) and ALDH2 protein (Figure 3B) expres-
sion levels did not differ among three groups. In contrast, ALDH 
activity in ALDH2*1/*2 and ALDH2*2/*2 mice was significantly 
lower than that in ALDH2*1/*1 mice (Figure 3C).
Next, we investigated the effect of ALDH2 genotype in mice 
on alcohol consumption as well as alcohol-derived DNA damage 
in esophageal tissues. When mice were given 10% ethanol as 
substitute for water for 7 days, the average amount of ethanol 
consumption in ALDH2*1/*2 or ALDH2*2/*2 mice was signifi-
cantly less than that in ALDH2*1/*1 mice (Figure 4A). Alcohol 
drinking increased esophageal DNA damage represented by 
N2-ethylidene-dG levels in all groups. Of note, ALDH2*1/*2 and 
ALDH2*2/*2 mice showed significantly higher DNA damage than 
ALDH2*1/*1 mice (Figure 4B).
Figure 2. Genotyping of human ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 knock-in mice. (A) PCR images for mice Aldh2 (left panel), and human ALDH2 (right panel). 
Left lane in left and right panel: molecular weight (MW) marker, 100 base pair (bp) DNA ladder. PCR products of mice Aldh2 and human ALDH2 were 264 bp and 
790  bp, respectively. (B) Elimination of neomycin resistant gene. Left lane: MW marker (100  bp DNA ladder). PCR products of human ALDH2 with or without 
neomycin-resistant gene were 2498 bp and 748 bp, respectively. Neo (+): before elimination of neomycin resistant gene, Neo (–): after elimination of neomycin re-
sistant gene. (C) The PCR images (PCR-RFLP methods) for ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 mice. Left lane: MW marker (100 bp DNA ladder). Digestion of PCR 
products with AcuI harbored three bands (430, 235 and 83 bp) in ALDH2*1/*1 mice, four bands (665, 430, 235 and 83 bp) in ALDH2*1/*2 mice and two bands (665 and 
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Alda-1 treatment on ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*2/*2 mice
To investigate the effects of Alda-1, an ALDH2 activator, we 
intraperitoneally injected Alda-1 in ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*2/*2 mice. As shown in Figure 5A, Alda-1 significantly ele-
vated hepatic ALDH activity in all the human ALDH2 knock-in 
mice. The amount of alcohol drinking in ALDH2*1/*2 and 
ALDH2*2/*2 mice was significantly increased by Alda-1 treatment, 
but not in ALDH2*1/*1 mice (Figure 5B). Importantly, esophageal 
N2-ethylidene-dG level in both ALDH2*1/*2 and ALDH2*2/*2 mice 
with alcohol drinking were significantly reduced by Alda-1 treat-
ment despite the increased alcohol consumption, indicating the 
protective role of Alda-1 from alcohol-derived DNA damage in 
these mice (Figure 5C).
Effects of cyanamide, an ALDH2 inhibitor, on 
esophageal DNA damage in mice with alcohol 
drinking
Finally, we investigated whether cyanamide, an ALDH2 inhibitor, 
enhances alcohol-derived DNA damage in the esophagus of 
mice with alcohol drinking. As shown in Figure 6A, single 
intraperitoneal injection of cyanamide in C57BL/6N mice signifi-
cantly reduced hepatic ALDH activity. Thereafter, we injected cy-
anamide to the C57BL/6N mice and let them drink 10% ethanol 
for 7 days. Cyanamide treatment resulted in a significant reduc-
tion of alcohol consumption (Figure 6B); however, esophageal 
N2-ethylidene-dG level was conversely significantly exacerbated 
by cyanamide treatment (Figure 6C).
Discussion
In this study, we established novel genetic engineering mouse, 
human ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 knock-in 
mice. So far, Aldh2 knockout mice have been widely used as 
an experimental mouse model for analyzing Aldh2 function; 
however, because ALDH2 dysfunction in human being mainly 
occurs as a result of having ALDH2*2 allele, Aldh2 knockout mice 
do not serve as bona fide model of human diseases related to 
acetaldehyde. In addition, because Aldh2 knockout mice lack 
Aldh2 protein, they cannot be used for examining the effect 
of ALDH2 enzymatic modulator such as ALDH2 activator and/
or ALDH2 inhibitors. Indeed, treatment with ALDH2 activator 
(Alda-1) or ALDH2 inhibitor (cyanamide) did not affect Aldh2 
activity in Aldh2 knockout mice (data not shown). To overcome 
disadvantages of Aldh2 knockout mice, we generated human 
ALDH2 knock-in mice. In this study, we newly established mice 
model, in which mouse Aldh2 allele was replaced to human 
ALDH2*1 (wild-type allele) or ALDH2*2 (mutant allele) by hom-
ologous recombination, and neomycin-resistant genes are also 
removed using CAG promoter-mediated Cre-loxP system. Here, 
we showed that ALDH2 activity in ALDH2*1/*2 and ALDH2*2/*2 
Figure 3. Levels of ALDH2 expression and activity in human ALDH2*1/*1, 
ALDH2*1/*2 and ALDH2*2/*2 knock-in mice. (A) Hepatic ALDH2 messenger RNA 
(mRNA) expression levels in ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 mice: 
ALDH2 mRNA expression level was measured by real-time RT-PCR. Relative 
ALDH2 mRNA levels in the liver of ALDH2*1/*2 and ALDH2*2/*2 mice relative to 
that of ALDH2*1/*1 mice is indicated. β-actin served as an internal control. (NS, 
not significant versus ALDH2*1/*1; n = 3). (B) Hepatic ALDH2 protein expression in 
human ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 knock-in mice: ALDH2 protein 
expression was demonstrated by western blotting. β-actin served as a loading 
control. (C) Hepatic ALDH activity in ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 
mice. ALDH activity in mice with ALDH2*2 allele (ALDH2*1/*2 and/or ALDH2*2/*2 
mice) were significantly lower than that in ALDH2*1/*1 mice. n = 6 *P < 0.05 versus 
ALDH2*1/*1 mice.
Figure 4. Influences of alcohol drinking on human ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*2/*2 knock-in mice. (A) The amount of alcohol consumption per day in 
ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 mice. They were allowed to drink 10% 
ethanol freely for 7 days. The average amount of alcohol consumption per day 
in each mice is shown. n = 6*, *P < 0.05, versus ALDH2*1/*1 mice. (B) Esophageal 
N2-ethylidene-dG levels in ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 mice that 
were allowed to drink 10% ethanol or water for 7 days. Alcohol drinking signifi-
cantly increased esophageal N2-ethylidene-dG levels in all groups. Esophageal 
N2-ethylidene-dG levels in ALDH2*1/*2 and/or ALDH2*2/*2 mice with alcohol 
drinking were significantly higher than those in ALDH2*1/*1 mice with alcohol 
drinking. n = 6, *P < 0.05 versus each group of mice that drink water. *P < 0.05 
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mice was significantly lower than that in ALDH2*1/*1 mice, 
although the messenger RNA as well as protein expression 
levels of ALDH2 did not differ among them. Therefore, it is 
conceivable that reduced ALDH2 activity in ALDH2*1/*2 and/or 
ALDH2*2/*2 mice is caused by genetic polymorphism, but not by 
different expression levels of ALDH2. Notably, even with lesser 
amount of ethanol intake, esophageal DNA damage levels with 
alcohol drinking were significantly higher in ALDH2*1/*2 and 
ALDH2*2/*2 mice than those in ALDH2*1/*1 mice. This result 
suggests that esophagus of ALDH2*1/*2 and/or ALDH2*2/*2 mice 
is more susceptible to ethanol, probably due to decreased ac-
tivity of ALDH2. Taken together, we established experimental 
mice model that possess identical polymorphism seen in 
human ALDH2 gene and would serve as an ideal experimental 
model for studying human diseases associated with impaired 
ALDH2 activity.
Figure 6. Effect of cyanamide treatment on C57BL6 mice. (A) Hepatic ALDH ac-
tivity in C57BL/6N mice treated with cyanamide or vehicle control. Cyanamide or 
vehicle control (1.5 mg/kg body weight) was intraperitoneally injected to C57BL6 
mice, and then liver of those mice was collected 3 h after the injection and hep-
atic ALDH activity was measured. n = 6, *P < 0.05 versus control. (B) The amount 
of alcohol consumption per day in C57BL/6N mice treated with cyanamide or 
vehicle control. They were allowed to drink 10% ethanol freely for 7 days. The 
average amount of alcohol consumption per day in each mice is shown. n = 6, 
*P  <  0.05 versus control. (C) Esophageal N2-ethylidene-dG levels in C57BL/6N 
mice with alcohol drinking in the presence or absence of cyanamide treatment. 
Cyanamide treatment significantly increased esophageal N2-ethylidene-dG level 
in C57BL/6N mice with alcohol drinking, compared with control. n = 6, *P < 0.05 
versus control.
Figure 5. Effect of Alda-1 treatment on human ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*2/*2 knock-in mice. (A) Hepatic ALDH activity in ALDH2*1/*1, ALDH2*1/*2 
and ALDH2*2/*2 mice treated with Alda-1 or vehicle control. Alda-1 or vehicle 
control (20  mg/kg body weight) was intraperitoneally injected to ALDH2*1/*1, 
ALDH2*1/*2 and ALDH2*2/*2 mice, and then liver of those mice was collected 3 h 
after the injection and hepatic ALDH activity was measured. Alda-1 significantly 
increased hepatic ALDH activity in ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 mice. 
n = 8, *P < 0.05 versus each group of mice treated with vehicle control. (B) Amount 
of ethanol intake in ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 mice treated with 
Alda-1 or vehicle control. Alda-1 significantly increased the amount of al-
cohol drinking per day in both ALDH2*1/*2 and ALDH2*2/*2 mice. n = 8, *P < 0.05 
versus each group of mice treated with vehicle control. N.S.: no significant. (C) 
Esophageal N2-ethylidene-dG levels in ALDH2*1/*1, ALDH2*1/*2 and ALDH2*2/*2 
mice with alcohol drinking in the presence or absence of Alda-1 treatment. 
Alda-1 treatment resulted in a significant reduction of the N2-ethylidene-dG 
level in the esophagus of both ALDH2*1/*2 and ALDH2*2/*2 mice with alcohol 
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In this study, we used Alda-1, a small molecule compound 
that has been identified as ALDH2 activators, and examined 
its effects on human ALDH2 knock-in mice. Alda-1 has been 
firstly reported by Chen et  al., identified by high-throughput 
screening using a fluorescent ALDH2 enzymatic assay based on 
the emission of resorufin (40). It was shown to be effective for 
an ischemic damage to the heart (40) and an acute inflamma-
tory pain (50) in human ALDH2*1/*2 knock-in mice established 
in their group. In our present study, Alda-1 treatment signifi-
cantly restored ALDH2 activity in ALDH2*1/*2 and ALDH2*2/*2 
mice. It also increased the amount of alcohol drinking in those 
mice, nevertheless, esophageal DNA damage levels were sig-
nificantly reduced by Alda-1 treatment, presumably due to the 
increased ALDH2 activity by Alda-1 treatment. Conversely, treat-
ment with cyanamide, an ALDH2 inhibitor, reduced ALDH2 ac-
tivity in C57BL/6N mice. Despite that cyanamide decreased the 
alcohol consumption in those mice, esophageal DNA damage 
levels were significantly enhanced by cyanamide treatment. 
These results indicate that modulation of ALDH2 activity using 
ALDH2 activator (Alda-1) or ALDH2 inhibitor (cyanamide) deeply 
affects the levels of esophageal DNA damage associated with al-
cohol drinking. Moreover, because esophageal DNA damage has 
been linked to esophageal carcinogenesis (51), Alda-1 might be 
effective in the prevention of alcohol-mediated ESCC via restor-
ation of ALDH2 activity.
Molecular mechanisms underlying the activation of ALDH2 
by Alda-1 is previously reported by Perez-Miller et al., and they 
noted that Alda-1 increases ALDH2 enzymatic activity of ALDH2*2 
because it acts as a structural chaperon and it restores the ab-
normal structure of ALDH2*2 (41). Furthermore, Alda-1 activates 
both ALDH2*1 and ALDH2*2 by binding at the entrance of the 
catalytic tunnel in close proximity to Cys302 and Glu286, which 
are critical to its substrate catalysis (41). In line with their report, 
we showed that Alda-1 treatment increased ALDH2 activity not 
only in ALDH2*1/*2 and ALDH2*2/*2 but also in ALDH2*1/*1 mice. 
Our results were consistent with a previous report that Alda-1 
increased ALDH2 activity in human ALDH2*1/*1, ALDH2*1/*2 and 
ALDH2*2/*2 knock-in mice that were established by other groups 
independently (50). Although Alda-1 did not affect alcohol con-
sumption as well as DNA adduct level in ALDH2*1/*1 mice, we 
presume that basal ALDH2 activity in wild-type ALDH2 might 
be inherently sufficient, and the increase of ALDH2 activity by 
Alda-1 in ALDH2*1/*1 may not have substantial benefit for pro-
tecting esophageal DNA damage.
In this study, we did not find histological abnormalities in the 
esophagus of ALDH2*1/*2 and ALDH2*2/*2 mice after drinking 
alcohol for 7  days. Although we made ALDH2*1/*2 mice drink 
10% alcohol for as long as 12 months, even those mice did not 
develop esophageal cancer (data not shown). We suspect that 
more long-time drinking may be necessary for a development 
of ESCC, or other factors besides alcohol drinking alcohol may 
also be involved in the development of esophageal cancer, as 
there has been a report that esophageal dysplasia was caused 
by 4-nitroquinoline-1-oxide and ethanol intake for 10 weeks 
(52). Furthermore, we may be able to test the preventive effect 
of Alda-1 on alcohol-mediated ESCC development with those 
models.
The limitation of our study is that we could not evaluate the 
influences of Alda-1 on alcohol-abuse. As cyanamide is used as 
an alcohol deterrent drug for alcoholics, ALDH2 activators may 
have the risk of alcohol abuse due to enabling more alcohol 
drinking and therefore alcohol abuse. We should further define 
the indication for treatment of ALDH2 activators as a preventive 
agent for ESCC.
In conclusion, we established a novel mice model representing 
human ALDH2 gene polymorphism which causes reduced ALDH2 
activity and is associated with various diseases including ESCC. 
We further showed that ALDH2 activation by Alda-1 in mice with 
ALDH2 dysfunction alleviates esophageal DNA damages associ-
ated with alcohol drinking. Our findings provide a new insight 
into alcohol-mediated esophageal carcinogenesis and prevention.
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